Enbrel (etanercept) / Pfizer, Amgen - LARVOL DELTA

Aged B cells as a candidate cell of origin for diffuse large B cell lymphoma: A multi-modal analysis of somatic mutation, clonality, and transcriptional programs (ASH 2025) - "To establish a biological connection between ABCsand DLBCL, we analyzed paired blood and tumor samples to identify shared mutations and CDR3 clones.Longitudinal immune monitoring in autoimmune patients treated with biologic agents (adalimumab,belimumab, etanercept) was used to assess treatment-related changes in ABC dynamics. Our findings implicate ABCs as a likely reservoir of lymphoma-initiating clones and a candidate cell oforigin for DLBCL. The enrichment of AID-driven mutations, clonal dominance, and overlapping betweenABC and tumor clones supports a model in which aberrant persistence and ongoing mutagenesis in ABCspromote lymphomagenesis. This work establishes a framework for mutation-informed MRD surveillanceand highlights the clinical relevance of ABC biology across both AI and B cell malignancy."

B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • AICDA • ARID1A • CD14 • ITGAX • ITGB2 • KMT2D • PRDM1 • ZEB2

Impact of ruxolitinib on corticosteroid treatment patterns in 1147 patients with chronic graft-versus-host disease in real-world practice in the United States: A long-term follow-up analysis (ASH 2025) - "Prescription refills in pharmacy claim records wereused to determine RUX and prednisone-equivalent CS dosing and treatment length. Line of therapy forcGVHD medications was based on claims for CS, belumosudil, abatacept, alemtuzumab, RUX, etanercept,hydroxychloroquine, ibrutinib, imatinib, interleukin-2, methotrexate, mycophenolate mofetil, pentostatin,and rituximab after cGVHD diagnosis... Patients treated with RUX for cGVHD in real-world clinical practice remained on treatmentfor a median of 8 months; 40.9% remained on RUX for 1 year and 21.3% for 2 years, suggesting long-termpersistence of safety and ongoing clinical benefit. Median time from earliest CS fill for cGVHD todiscontinuation or reduction to low-dose CS was 77 days. By the end of 1-year follow-up, 90% of patientsachieved discontinuation or reduction to low-dose CS."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • IL2

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

O05 A retrospective review of cases of psoriasis requiring discontinuation of biologic therapy from 2007 to 2024 in a multisite NHS trust. (PubMed, Br J Dermatol) - "Concurrent systemic immunosuppression (methotrexate or ciclosporin) was prescribed in 21% (n = 31)...The biologics with most interventions were adalimumab or biosimilars (n = 102: Humira n = 39, Idacio n = 30, Hyrimoz n = 23, Amgevita n = 10), ustekinumab (n = 39), secukinumab (n = 35), guselkumab (n = 13) and certolizumab (n = 11)...The main blood abnormality was positive tuberculosis ELISpot assay (interferon-γ release assay) (n = 6: Humira n = 2; and Idacio, ustekinumab, etanercept and risankizumab n = 1 each). Other abnormalities included leucocytosis in sepsis (n = 2; ustekinumab, secukinumab), neutropenia (n = 1; Hyrimoz), raised alanine aminotransferase (n = 1; Humira) and raised fetal calprotectin (n = 1; Ixekizumab)...Blood abnormalities requiring treatment intervention were infrequent, most commonly positive tuberculosis testing. Our findings support reducing blood monitoring of..."

Journal • Retrospective data • Atopic Dermatitis • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Neutropenia • Pain • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • Seronegative Spondyloarthropathies • Tuberculosis • Type 2 Diabetes Mellitus • Ulcerative Colitis • Urticaria • IFNG

The diagnostic and therapeutic challenges of pyoderma gangrenosum in a 32-year-old woman with systemic lupus erythematosus: a case report. (PubMed, Ann Med Surg (Lond)) - "Following an unsatisfactory response by prednisolone, azathioprine at a daily dose of 150 mg, and mycophenolate mofetil at a daily dose of 2 g, etanercept (25 mg every other week) was administered. It also sheds light on maintenance of initial corticosteroid therapy and reconsideration of early dose tapering. Some uncommon and challenging presentation of pyoderma gangrenosum in a SLE patient may require an appropriate, individualized management."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Oncology • Pain • Pyoderma Gangrenosum • Systemic Lupus Erythematosus • Vasculitis

Safety profile of TNF- alpha Inhibitors in pediatric patients: A post-marketing surveillance study based on the FAERS database. (PubMed, PLoS One) - "This study systematically evaluated the safety profile of tumor necrosis factor-alpha (TNF-α) inhibitors in pediatric patients using data from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) from Q1 2004 to Q3 2024.Through disproportionality analysis of adverse event (AE) reports for infliximab, etanercept, adalimumab, golimumab and certolizumab, we identified 852 significant safety signals spanning 27 system organ classes (SOCs). While these agents remain vital for managing chronic inflammatory diseases, the findings advocate for enhanced clinical vigilance. We propose a tiered monitoring protocol prioritizing infection surveillance (e.g., serial inflammatory markers), systematic injection-site evaluations, and longitudinal organ function assessments, particularly during the initial treatment phase, to optimize therapeutic risk-benefit ratios."

Journal • P4 data • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Pediatrics

Serious Infections in Offspring Exposed to Tumour Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability. (PubMed, Arthritis Rheumatol) - "Overall, TNFi exposure was not associated with serious infections; exploratory signals by timing and placental transfer were imprecise and require confirmation."

Journal • Infectious Disease • Oncology

Hepatitis B reactivation linked to tumor necrosis factor-α inhibitors in rheumatoid arthritis: a systematic review and meta-analysis. (PubMed, Cell Mol Biol (Noisy-le-grand)) - "HBVr rates also varied by TNFi type, with 4% for adalimumab, 3% for etanercept, and 2% for infliximab. Overall, TNFi therapy in HBV-related RA is associated with a low but clinically relevant risk of HBVr, with higher rates in HBsAg-positive patients and modest variation by region and drug type, while antiviral prophylaxis and glucocorticoid use appear to have no significant effect on risk."

Clinical • Journal • Retrospective data • Review • Hepatitis B • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology

Influence of anti-tumor necrosis factor (TNF) treatments on T cell cytokine production in patients with inflammatory joint diseases - comparison of etanercept and anti-TNF monoclonal antibodies. A double-blind, prospective, placebo-controlled study. (PubMed, J Physiol Pharmacol) - "In summary, we ascertain that treatment with TNF inhibitors does not affect Th1, Th2, or Th17 responses. Etanercept and monoclonal antibodies differ in their effect on IL-17A+DN T cells."

Clinical • Journal • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • CD4 • CD8 • IFNG • IL17A • IL4

A comparative analysis of biologics market dynamics in 12 countries: (Bio)similar and sustainability. (PubMed, Front Pharmacol) - "Group A consisted of biologics with biosimilars-etanercept, infliximab, rituximab, and trastuzumab, while Group B comprised biologics without biosimilars, including cetuximab, nivolumab, and pembrolizumab. The introduction of biosimilars was significantly associated with reductions in the prices and expenditures of biologics in high-income countries. This underscores the potential role of biosimilars in supporting the long-term sustainability of the healthcare system."

Journal • Oncology

Successful treatment of post-transplant steroid-refractory idiopathic pneumonia syndrome with etanercept and mycophenolate mofetil (PubMed, Rinsho Ketsueki) - "As of day 636, he is in remission of leukemia without recurrence of IPS. Our case suggests that prompt MMF therapy is an option for steroid-refractory IPS that does not adequately respond to etanercept."

Journal • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases • Transplantation

Efficacy and Safety of Biologics in the Treatment of Pediatric Psoriatic Arthritis: A Systematic Review. (PubMed, J Cutan Med Surg) - No abstract available

Journal • Dermatology • Immunology • Inflammatory Arthritis • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Assessment of myocardial structure and function in rheumatoid arthritis patients treated with biologics: tumor necrosis factor inhibitors and anti-interleukin-6 versus conventional disease-modifying drugs. (PubMed, Reumatologia) - "This study aimed to compare treatment options: one combination of tumor necrosis factor inhibitors (adalimumab, etanercept) with methotrexate (MTX) and second treatment with anti-interleukin-6 (tocilizumab) - to determine whether cardiovascular effects are driven primarily by disease activity reduction or through distinct effects based on the mechanism of action. Biologics, irrespective of their specific mechanisms, significantly reduce disease activity, which positively influences LV mass and reduces the incidence of LV hypertrophy. Additionally, biologics do not adversely affect cardiac electrical function."

Journal • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Heart Failure • Immunology • Inflammatory Arthritis • Myocardial Infarction • Oncology • Rheumatoid Arthritis • Rheumatology • IL6

Pharmacogenomic landscape of TNF inhibitors in the Middle Eastern Qatari population. (PubMed, Front Immunol) - "High frequency of rs1800629 (TNF), rs1800896 (IL10), and rs1143634 (IL1B) variants are observed, which are known to be associated with responses to Etanercept and Infliximab. Moreover, we identified that PSORS1C1 has the highest CAPLoF (cumulative allele probability) scores for loss-of-function variants, which is associated with response to Etanercept and Adalimumab. The findings of this study will enhance our understanding of the pharmacogenomics of TNF inhibitors in Qatar and beyond, while also supporting the study of genetics in underrepresented populations."

Biomarker • Journal • Immunology • Oncology • IL10 • IL1B

Tocilizumab-Induced Bullous Rheumatoid Neutrophilic Dermatitis: A Rare Steroid-Resistant Adverse Effect Managed with Etanercept. (PubMed, Mod Rheumatol Case Rep) - "Despite corticosteroid therapy and colchicine, his symptoms persisted. Early identification through skin biopsy, prompt discontinuation of the offending agent, and consideration of targeted immunomodulators such as TNF-α inhibitors are critical in managing drug-induced RND. Continued documentation of such cases will enhance understanding of paradoxical inflammatory responses to biologic agents and inform future therapeutic approaches in patients with autoimmune diseases."

Adverse events • Journal • Dermatitis • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL6

Effectiveness of "tumor necrosis factor inhibitors" in monogenic hereditary recurrent fevers in children and adolescents: a systematic review. (PubMed, Front Immunol) - "Etanercept was the most frequently used TNF inhibitor (10/11 cases), and infliximab was used in one FMF case...TNFi may offer a therapeutic option for selected pediatric HRF cases, particularly colchicine-resistant FMF with articular symptoms or where IL-1 blockers are unavailable. However, their efficacy appears limited and variable across HRF subtypes. Larger studies are needed to better define the role of TNF inhibitors in pediatric HRFs."

Journal • Review • Oncology • Pediatrics • Rheumatology

Exploring the therapeutic effects of intensified immunosuppressive regimen for preengraftment syndrome after umbilical cord blood transplantation. (PubMed, Clin Exp Med) - "Optimal treatment strategies for PES remain unclear.This study aims to explore the therapeutic effects of post-transplant cyclophosphamide (PTCy), etanercept, and methylprednisolone in the treatment of PES. Thirdly, the intensified immunosuppressive regimen had no effect on donor cell engraftment, the recurrence of malignant diseases or survival outcomes. The combination of PTCy, etanercept, and methylprednisolone represents an effective treatment strategy for PES and reduces the incidence of aGVHD, albeit with an increased risk of viral infections."

Journal • Acute Graft versus Host Disease • Epstein-Barr Virus Infections • Graft versus Host Disease • Immunology • Infectious Disease • Transplantation

Mixed histiocytosis of the thoracic dura: a rare presentation of Mixed Erdheim-Chester Disease and Rosai-Dorfman Disease mimicking IgG4-Related Disease (SNO 2025) - "He received high dose prednisone and etanercept without radiographic or clinical improvement...He was treated with radiation therapy targeting the dural lesion with temporarily worsening symptoms improved with steroids and started on cobimetinib. A 50-year-old man presented for evaluation of spastic paraparesis in the context of a thoracic dural lesion. Two years prior he developed an inflammatory monoarthritis concerning for rheumatoid arthritis unresponsive to methotrexate. Six months prior he developed leg spasms, gait spasticity, and urinary incontinence."

CNS Disorders • Fibrosis • Genetic Disorders • Immunology • Inflammation • Inflammatory Arthritis • Movement Disorders • Otorhinolaryngology • Rare Diseases • Rheumatoid Arthritis • Rheumatology • Urinary Incontinence • Urology • BRAF • CCND1 • CD163 • CD1a • F13A1 • MAP2K1

Cyclosporine-induced paronychia in a case of Stevens-Johnson Syndrome (ISDS 2025) - "Case Report: A 32-year-old female received Leflunomide for arthralgias, after which she developed Stevens-Johnson Syndrome with severe mucous membrane affection...After which she received a single etanercept 150 mg injection together with increasing the dose of cyclosporine to 300 mg according to her weight, with gradual improvement of the condition and tapering of steroids over the next week...The condition continued to exacerbate over the next two weeks, even after decreasing the dose of cyclosporine, and only improved after nail detachment despite receiving antibiotics and chymotrypsin... Acute severe painful paronychia could be encountered in cases of Stevens-Johnson Syndrome receiving cyclosporine and can be explained by the disease insult on the periungual tissue or the inflammatory proliferative status of cyclosporine."

Clinical • Dermatology • Immunology • Infectious Disease • Inflammation • Mood Disorders • Musculoskeletal Pain • Pemphigus Vulgaris • Steven-Johnson Syndrome • CD20 • CXCL8 • EGFR • IL6

Common Psoriasis Therapeutics and Ocular Symptoms: Analysis of the FAERS Database (ISDS 2025) - "OAE for adalimumab, apremilast, etanercept, infliximab, ustekinumab, guselkumab, and secukinumab were queried from the FAERS Database with disproportionality analysis (DA) conducted for top 25 OAEs. Apremilast, however, was only associated with increased risk of blepharospasm (16.43); all other adverse events studied displayed no increased risk. Our findings support the necessity of physician guidance and the research needed in elucidating ocular adverse events."

Age-related Macular Degeneration • Cataract • CNS Disorders • Dermatology • Dry Eye Disease • Glaucoma • Immunology • Keratitis • Macular Degeneration • Ocular Inflammation • Ophthalmology • Psoriasis • Retinal Disorders • Uveitis • ROR1

Guselkumab Pharmacokinetics and Immunogenicity in Pediatric Psoriasis: Phase 3 PROTOSTAR Study (ISDS 2025) - P3 | "In Part 1 (Weeks [W] 0–16), participants were randomized to GUS, placebo, or open-label etanercept. The development and titers of Ab to GUS did not impact PK or clinical response. The observed PK for GUS in pediatric PsO participants receiving WB dosing was generally comparable with PK in adults with PsO."

Clinical • P3 data • PK/PD data • Dermatology • Immunology • Pediatrics • Psoriasis

Impact of Biologic Class on Ocular Outcomes in Psoriasis: Insights from a Multi-Institutional Database Study (ISDS 2025) - "Adults aged 18–89 years with psoriasis who initiated either TNFα inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) or IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) within one year of diagnosis were identified. In this large, multi-institutional analysis, psoriasis patients treated with TNFα inhibitors experienced higher rates of several ocular inflammatory and degenerative conditions compared to those treated with IL-17 inhibitors. These findings highlight the importance of considering ocular comorbidity risk when selecting biologic therapy for psoriasis."

Clinical • Cataract • Conjunctivitis • Dermatology • Dry Eye Disease • Immunology • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Psoriasis • Uveitis • IL17A

Global burden of TNF-α inhibitors associated demyelinating diseases: A global disproportionality analysis. (PubMed, Medicine (Baltimore)) - "Five TNF-α inhibitors (infliximab, adalimumab, etanercept, certolizumab pegol, and golimumab) were included in this study. Clinicians should remain vigilant for neurological symptoms in patients receiving these therapies. Although this disproportionality analysis did not permit causal interpretation, it is important to recognize that the therapeutic benefits of TNF-α inhibitors in managing inflammatory and autoimmune diseases may still outweigh these potential risks."

Journal • Observational data • CNS Disorders • Immunology • Multiple Sclerosis • Oncology

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors. (PubMed, Rheumatol Ther) - "Patients with active PsA initiating guselkumab were significantly (approximately two times) more likely to remain persistent with on-label therapy through 24 months versus SC TNFi, overall and among biologic-naïve and biologic-experienced subgroups."

Journal • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies